Virtuoso Therapeutics to present at AACR annual meeting Virtuoso Therapeutics will present two posters at the American Association for Cancer Research (AACR) 2022 annual meeting. The posters will highlight the company's preclinical data from its leading bispecific antibody programs, the company said.Read More
Inhibrx to present at 2022 AACR annual meeting Inhibrx will present preclinical data from INBRX-121 and INBRX-130 at the 2022 annual meeting for the American Association for Cancer Research (AACR), held on April 8-13.Read More
Personalis to present at AACR annual meeting 2022 Precision oncology firm Personalis will present new data at the scientific poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022, held April 8-13.Read More
Nucleai closes $33M series B financing Artificial intelligence-powered spatial biology company Nucleai closed a $33 million series B financing round, which it will use to advance its spatial biology platform for drug research, development, and diagnostics.Read More
Waters develops mass and purity automated analyzer for biomolecules Waters has introduced a new software alongside analytical columns to assist in the drug development and biomolecule discovery process. The Waters Intact Mass app on waters_connect enables the confirmation of the mass and purity of biomolecules in a process that is twice as fast as current commercial technologies, the company said.Read More
Seqens invests in U.S. R&D lab facility Seqens has made a multimillion-dollar investment into its research and development laboratory based in Devens, MA. The project is expected to be completed in October 2022, the company said.Read More
Sengenics launches autoantibody profiling service Sengenics has launched a new autoantibody profiling service that could improve the discovery of autoantibody disease biomarkers. The profiling service, known as the Pan-Autoimmune Protein Array 1.0, is a multiplexed immunoassay based on protein microarrays.Read More